About Contact Us Careers

Gangrene Treatment Market Size & Share, by End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers [ASCs], Wound Care Centers); Cause, Type; Treatment; Route of Administration; Distribution Channel - Global Growth Forecasts & Statistical Report 2026-2035

  • Report ID: 3076
  • Published Date: Oct 01, 2025
  • Report Format: PDF, PPT

Gangrene Treatment Market Outlook:

Gangrene Treatment Market size was USD 2.1 billion in 2025 and is anticipated to reach USD 3.8 billion by the end of 2035, increasing at a CAGR of 6.8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of gangrene treatment is estimated at USD 2.2 billion.

The international market is uplifting, owing to a rise in the patient pool, due to an upsurge in the incidence of peripheral artery disease, diabetes mellitus, and traumatic injuries. According to a report published by the CDC in May 2024, 38.4 million people, or 11.6% of the population in the U.S., are readily affected with diabetes. In addition, 38.1 million adults aged more than 18 years, which is 14.7% of adults in the country, comprised diabetes, thereby leading to an increase in the market’s exposure. Besides, nearly 8.7 million adults within the same age range have successfully met laboratory criteria for the condition, which is also driving the market demand.

Moreover, the supply chain dynamic in the market takes into consideration the gangrene-related therapeutics and devices production that effectively depends on the international APIs chain, surgical tools, hyperbaric systems, and wound dressing. As per the July 2024 AHA Organization data report, the U.S. heavily relies on China for medical supplies and equipment, and the country has readily imported USD 14.9 billion, in comparison to USD 14 billion the previous year. Besides, an estimated 10.5% of global hospitals’ budget, catering to medical supply costs has successfully accounted for USD 146.9 billion as of 2023, denoting an increase of more than USD 6.6 billion as of 2022.

Gangrene Treatment Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • An increase in government healthcare expenditure: The aspect of an increase in Medicare and Medicaid services has effectively reflected the surging need, owing to the incidence of diabetes and an increase in the elderly population globally, which has positively impacted the market across different nations. Besides, as per an article published by Rare Diseases India in December 2024, the regional government established the National Fund for Rare Diseases (NFRD), with the provision of ₹974 crore (USD 110 million) for the financial year of 2024 and 2025. Therefore, with an increase in chronic conditions, the government has come forward to ensure federal spending, thus suitable for the market’s upliftment.
  • Enhanced patient pool with chronic diseases: These conditions effectively demand continuous medical attention as they tend to limit activities of daily living, which is also proliferating the market. As per the October 2024 CDC data report, chronic conditions cater to USD 4.9 trillion in yearly healthcare care expenses. Besides, 6 in 10 people from America are affected with almost one chronic disease, and 4 in 10 have more than two chronic diseases. This growing patient pool continues to bolster the market for early diagnosis, wound management products, and advanced surgical treatments requirements.
  • Chemical advancements in wound care: The creation and incorporation of antimicrobial dressings, foam dressings, hydrocolloids, and bio-engineered skin substitutes leads to improving healing rates and combat infection risk, which is also uplifting the global market. According to the May 2022 NLM article, epithelial keratins comprise 1% of sulfur, along with 3% of cysteine, suitable for stabilizing cells in epithelia. Besides, trichocyte keratins constitute 5% of sulfur, along with 4% to 17% of cysteine, thus also suitable for healing wounds. Therefore, the presence of these chemicals is a huge growth factor for the overall market across different nations.

Antimicrobial Resistance (AMR) Driving the Market

Components

Incidence/ Rate

Bacterial AMR

1.2 million global deaths (2023)

Additional healthcare expenses

USD 1 trillion (2050)

Gross domestic product (GDP) loss

USD 3.4 trillion (2030)

Third-generation cephalosporin-resistant E. coli presence

42% across 76 nations

Methicillin-resistant Staphylococcus aureus presence

35%

Urinary tract infections caused by E. coli

1 in 5 cases

Source: World Health Organization (WHO)

Challenges

  • Pricing restrictions and caps in government healthcare: Several countries have robust price caps on the advanced treatments for gangrene. This high cost is within their government-funded healthcare systems. For instance, in 2023, a company collaborated with a health authority in Germany to overcome these challenges in pricing, hence boosting the market access by 10.2%. Apart from these, reimbursement challenges often restrict the use of high-cost advanced biologic dressings by 20.2% among hospital patients.

Gangrene Treatment Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2025-2037

CAGR

6.8%

Base Year Market Size (2025)

USD 2.1 billion

Forecast Year Market Size (2035)

USD 3.8 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Gangrene Treatment Market Segmentation:

End user Segment Analysis

Based on the end user, the hospitals segment is anticipated to garner the largest share of 55.8% by the end of 2035. The segment’s upliftment is highly attributed to hospitals being considered the pivotal treatment center for patients suffering from gangrene, and are generously funded in different regions, leading to a maximization across wound care departments, particularly for the diabetic and elderly population internationally. Besides, the aspect of reimbursement in Medicare has a wide-ranging space for post-operative and surgical wound management services to bolster the patient inflow. Meanwhile, the WHO’s international plan has stressed the infection control infrastructure development, especially in hospital settings, which has reinforced the tendency, thus driving the segment’s growth.

Cause Segment Analysis

Based on the cause, the ischemic gangrene segment is projected to cater to the second-largest share in the market during the projected timeline. The segment’s growth is highly fueled by its potential to be a progressive and life-threatening condition that frequently leads to critical morbidity, mortality, and a significant reduction in the quality of life of patients. As per an article published by NLM in July 2025, the yearly incidence of gangrene is estimated to be 16.7%, which is caused by peripheral vascular disorder. Additionally, the critical limb ischemia incidence is 1% in the U.S., which is majorly observed among patients aged more than 50 years, thereby uplifting the segment.

Type Segment Analysis

Based on type, the wet gangrene segment is expected to account for the third-largest share by the end of the projected duration. The segment’s development is highly driven by its severity and rapid progression in bacterial infection in dead tissue, which is frequently caused by restricted blood supply. This eventually leads to life-threatening conditions, such as septic shock and sepsis, requiring immediate medical intervention. Besides, wet gangrene develops when the body tissue is readily impaired with arterial or venous blood flow, leading to severe infection, which in turn, denotes a huge growth opportunity for the overall market.

Our in-depth analysis of the global market includes the following segments:

Segment

Subsegments

End user
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Wound Care Centers
  • Others

Cause
  • Ischemic Gangrene
  • Antibiotic Therapy
  • Debridement
  • Hyperbaric Oxygen Therapy (HBOT)
  • Vascular Surgery
  • Amputation
  • Rehabilitation Therapy
  • Supportive Care
  • Infectious Gangrene
  • Traumatic Gangrene
  • Post-Surgical Gangrene

Type
  • Wet Gangrene
  • Dry Gangrene
  • Gas Gangrene
  • Fournier's Gangrene
  • Internal Gangrene

Treatment
  • Antibiotic Therapy
  • Penicillin
  • Tetracycline
  • Aminoglycosides, Cephalosporins
  • Others
  • Debridement
  • Surgical
  • Mechanical
  • Autolytic
  • Enzymatic
  • Hyperbaric Oxygen Therapy (HBOT)
  • Vascular Surgery
  • Bypass Surgery
  • Angioplasty & Stenting
  • Amputation
  • Minor
  • Major
  • Rehabilitation Therapy
  • Supportive Care
  • Oral
  • Injectable
  • Topical
  • Others

Route of Administration

  • Oral
  • Injectable
  • Topical
  • Others

Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Gangrene Treatment Market - Regional Analysis

North America Market Insights

North America market is expected to garner the highest share of 35.2% by the end of 2035. The market’s growth in the region is highly driven by the federal healthcare budget, advancements in surgical and wound care solutions, import dependency on the international supply chain for surgical instruments, and an increase in government-based funding for innovation. As per an article published by AHRQ in September 2024, there has been an increase in hospital expenses in the U.S. from USD 31.3 billion to USD 52.1 billion, which is positively impacting the overall market in the region.

The gangrene treatment market in the U.S. is growing significantly, owing to the presence of NIH funding for infectious diseases, increased integration of wound dressing systems, generous sourcing of medical instruments, federal spending, and an expansion in Medicare and Medicaid reimbursement services. As stated in the 2025 OEC data report, the country is one of the leading exporters of medical instruments, with a valuation of USD 34.8 billion, and USD 37.7 billion in terms of imports, which is significantly uplifting the market’s development. Besides, the focus on limb preservation, as well as infection control facility is also responsible for positively impacting the market in the country.

2023 Medical Instruments Across Other Countries in North America

Countries

Export

Import

Mexico

USD 17.6 billion

4.6 billion

Canada

USD 1.2 billion

USD 3.7 billion

Costa Rica

USD 5.9 billion

USD 828 million

Dominican Republic

USD 2.1 billion

USD 201 million

Guatemala

-

USD 117 million

Panama

-

USD 110 million

Source: OEC

APAC Market Insights

Asia Pacific in the gangrene treatment market is projected to emerge as the fastest-growing region during the predicted timeline. The market’s development is highly fueled by an increase in the aging population, an expansion in healthcare facilities as well as government investments, a rise in the incorporation of progressive treatment modalities, an upsurge in patient awareness, and the growing prevalence of peripheral artery disorder. According to the November 2023 ADBI Institute report, the universal health coverage in the Republic of Korea took almost a year to be achieved, resulting in an increased GDP of USD 1,055.9 to USD 5,817, thus denoting a huge growth opportunity for the market in the overall region.

The gangrene treatment market in India is gaining increased traction, owing to the availability of healthcare and medical reforms, increase in number of patients, an expansion in private and public healthcare industries, an increase in awareness through campaigns, along with government’s strategies, which are readily focused on enhancing funding for infection prevention and chronic wound care. As stated in the May 2024 NLM article, under the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM ABHIM), the overall financial outlay for the 5-year scheme period is account for USD 7.8 billion, with the objective of supporting both urban and rural healthcare centers, public health laboratories, and public health units, all of which cater to the market’s upliftment.

Europe Market Insights

Europe in the gangrene treatment market is predicted to grow steadily by the end of the forecast duration. The market’s growth in the region is highly attributed to a rise in healthcare spending, robust government approaches, an increase in surgical debridement, biologics, and hyperbaric oxygen therapy adoption, generous sourcing of medical, surgical, and lab-based sterilizers, and harmonization in reimbursement policies. According to the May 2024 NLM article, the domestic Center for Disease Prevention and Control report occurrence rates have increase for surgical site infection from 0.6% for knee surgery to 9.5% for open colon surgery, thus driving the market’s exposure.

The gangrene treatment market in the UK is gaining increased exposure, owing to the National Health Service (NHS) readily prioritizing limb preservation programs, the growing incidence of rare diseases, an increase in government investment for progressive preventive care, the Association of the British Pharmaceutical Industry (ABPI), public awareness campaigns, and integrated digital health solutions. As per the 2023 NHS England data report, an amount of £107.8 billion has been initiated for promoting localized health services, along with £29.8 billion for catering to primary care services and personalized public health service, thereby suitable for boosting the overall market.

Medical, Surgical, or Laboratory Sterilizers 2023 Export and Import in Europe

Countries

Export

Import

Italy

USD 193 million

USD 15.4 million

Germany

USD 104 million

USD 52.3 million

Poland

USD 51.6 million

USD 18.8 million

France

USD 21.5 million

USD 41.9 million

Spain

USD 48.2 million

USD 18.4 million

UK

USD 12.4 million

USD 27 million

Source: OEC

Gangrene Treatment Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Gangrene Treatment Market Players:

Recent Developments

  • In March 2025, Mölnlycke declared that it has successfully signed an agreement to gain P.G.F. Industry Solutions GmbH, with the objective of consolidating its position as the ultimate international leader in wound care.
  • In November 2024, BioStem Technologies Inc. notified that it has signed a letter of intent (LOI) to effectively achieve commercial-based product, along with developmental technologies from ProgenaCare Global LLC.
  • Report ID: 3076
  • Published Date: Oct 01, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of gangrene treatment is evaluated at USD 2.1 billion.

Gangrene Treatment Market size was USD 2.1 billion in 2025 and is anticipated to reach USD 3.8 billion by the end of 2035, increasing at a CAGR of 6.8% during the forecast period, i.e., 2026-2035.

North America industry is predicted to account for the largest share of 35.2% by 2035, owing to a rise in wound care solutions as well as medical instrument sourcing in the region.

The major players in the market are Pfizer Inc., Antidote Therapeutics, Inc., Ixaka Ltd, Pluristem Therapeutics Inc., LimFlow SA, and others.

Gangrene Treatment Market Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos